Elevated serum Dickkopf-1 is a biomarker for bone erosion in patients with psoriatic arthritis

Yukchiu Chung1, Zhi-Chang Li2, Xiao-Lin Sun1, Yan-Ying Liu1, Miao Shao1, Yu-Zhou Gan1, Yi-Min Li1, Yu-Hui Li1, Xue-Wu Zhang1

1Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing 100044, China; 2Arthritis Clinic and Research Center, Peking University People’s Hospital, Beijing 100044, China.

Abstract
Background: Psoriatic arthritis (PsA) is an inflammatory arthropathy characterized by psoriasis and bone erosion on radiology. Dickkopf-1 (Dkk-1) is considered to be the main inhibitor of the Wnt signaling pathway and results in reduced osteoblast proliferation. The aim of this study was to investigate the serum level of Dkk-1 and its association with bone erosion in PsA patients.

Methods: Serum Dkk-1 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 69 patients with PsA and 60 controls, including 39 rheumatoid arthritis (RA) patients, and 21 healthy controls (HCs). Rheumatoid factor and anti-cyclic citrullinated peptide levels were also determined by ELISA. The association of Dkk-1 level with clinical and laboratory features of PsA was analyzed. Logistic regression analysis was used to analyze the risk factors for bone erosion in PsA.

Results: Dkk-1 was elevated in 68.1% (47/69) of the patients with PsA, 46.2% (18/39) of RA patients, and 9.5% (2/21) of HCs. Serum Dkk-1 concentration was significantly higher in PsA patients compared with that in HCs. The level of serum Dkk-1 was correlated with a swollen joint count, and levels of complement components 3 and 4. Elevated Dkk-1 level (odds ratio = 4.440, 95% confidence interval: 1.246–15.817, P = 0.021) was identified as the risk factor for bone erosion in PsA.

Conclusions: The serum level of Dkk-1 is abnormally elevated in PsA patients. The elevation of Dkk-1 might be involved in the mechanism of bone erosion in patients with PsA.

Keywords: Dickkopf-1; Psoriatic arthritis; Bone erosion

Introduction
Psoriatic arthritis (PsA) is an autoimmune inflammatory disease characterized by peripheral arthritis, spondylitis, enthesitis, dactylitis, and skin psoriasis.[1,2] Progressive bone destruction and aberrant new bone formation can be observed over the course of PsA.[3,4] Laboratory markers in PsA are non-specific, and there is no specific autoantibody distinguishing PsA from other inflammatory arthritis conditions. Elevated inflammatory reactants can be seen in about 30% to 40% of patients with PsA, including white blood cells (WBCs), C-reactive protein (CRP), and blood sedimentation, so-called acute phase reactants that are common but not specific.[4]

The Wnt/β-catenin pathway, considered the classical Wnt signaling pathway, is essential in regulating osteoblast proliferation, maturation, differentiation, and function.[5] Dickkopf-1 (Dkk-1) is a natural inhibitory factor of the Wnt/β-catenin pathway, promoting phosphorylation and subsequent degradation of β-catenin, thereby decreasing bone-forming osteoblasts and increasing bone-resorbing osteoclasts and resulting in a bias toward bone erosion.[6,7] Dkk-1 was involved in bone erosion and inflammation in rheumatoid arthritis (RA).[8] However, the potential role of Dkk-1 in PsA patients is controversial,[9,10] and the relationship between Dkk-1 levels and pathogenesis of bone remodeling in inflammatory arthritis is still uncertain.[9-11]

Thus, in our study, we detected the expression of Dkk-1 in serum of PsA patients, compared the level with those of RA and healthy controls (HCs), and analyzed the association between Dkk-1 with clinical and laboratory characteristics of PsA, focusing on its correlation with bone erosion.
We collected patients
Clinical and laboratory evaluation
Determination of serum Dkk-1 levels
Methods

Ethics approval

This study was approved by the Ethics Committee of the Peking University People’s Hospital (No. 2017PHB165-01). All subjects provided written informed consent according to the Declaration of Helsinki.

Patients and controls

Sixty-nine PsA patients were enrolled in this study, during the period from February 2007 to April 2020. All patients fulfilled the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA. Serum samples were obtained and stored at −70°C until use. In addition, control samples were taken from 39 patients who met the revised American College of Rheumatology criteria for RA and 21 HCs at the same hospital.

Determination of serum Dkk-1 levels

 Serum levels of Dkk-1 were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Cloud-Clone Corp., Texas, USA). Reagent and sample preparation, and assay procedure were performed following the manufacturer’s instructions. Absorbance density at 450 nm wavelength was measured using an ELISA reader (Bio-Rad, Hercules, CA, USA). Dkk-1 concentrations were calculated with a standard curve.

Clinical and laboratory evaluation

We collected patients’ data from medical records, including age, sex, arthritis/psoriasis duration, initial manifestation of PsA, family history, nail psoriasis, dactylitis, enthesitis, uveitis, tender joint count, swollen joint count, WBC count, hemoglobin, platelet count, erythrocyte sedimentation rate, CRP, immunoglobulins (IgA/IgG/IgM), complement components 3/4 (C3 and C4), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody, and human leukocyte antigen-B27 (HLA-B27).

Radiographic assessments

Plain radiographic images of joints were obtained from the hospital’s electronic medical records system. The modified Sharp-van der Heide method was used to score radiographs of the hands of PsA patients noting erosion and joint space narrowing. According to the CASPAR definition, pathological ossification near joint margins (excluding osteophyte formation) was identified as radiographic evidence of new bone formation. Sacroiliitis was defined as a present by New York criteria radiological manifestation: grade ≥3 if unilateral; bilateral grade ≥2 if bilateral. Patients were classified as having PsA with or without the radiographic axial disease (RAD); in keeping with recent studies, the inflammatory RAD was defined as the presence of New York criteria sacroiliitis as above, and/or a number of marginal/paramarginal syndesmophytes of the spine was ≥1. At least one bone erosion observed on radiographs was considered erosive change. All radiographs and measurements were interpreted by a trained rheumatologist and expert radiologist who were blinded to patients’ information.

Statistics

Data were presented as n (percentage), mean ± standard deviation, or median (P25, P75). Statistical significance between groups was assessed with χ² tests, independent samples t-tests, and non-parametric tests in the case of two groups; and with χ² tests and one-way analysis of variance with Holm-Sidak multiple comparisons test for three groups. Pearson or Spearman rank correlation coefficients were used to exploring the relationship between Dkk-1 levels and clinical/laboratory parameters. The potential risk factors associated with bone erosion in PsA were analyzed using a logistic regression model. P values < 0.050 were considered significant. The cut-off value of Dkk-1 concentrations was determined using a receiver operating characteristic (ROC) curve.

Results

Characteristics of study participants

The major demographic, clinical and laboratory features, and radiographic evaluations are shown in Table 1. Among 69 patients with PsA, 56.5% were female, the mean age was 52.7±13.0 years, mean arthritis and psoriasis duration were 5.0 (1.6, 13.0) and 12.0 (5.0, 20.0) years, and 17.4% (12/69) of them had a family history of skin psoriasis or PsA. Nail psoriasis, dactylitis, enthesitis, and uveitis were observed in 43.5%, 10.1%, 27.5%, and 2.9% of the PsA patients, respectively. Positive RF (8.7% vs. 79.5%, P < 0.001), anti-CCP antibody (5.8% vs. 97.4%, P < 0.01) were found less frequently in PsA patients compared with RA patients. HLA-B27 was detected in 20.3% of PsA patients. Sacroiliitis on radiography was found in 46.4% (32/69) of the PsA patients. No significant differences in age, sex ratio, arthritis/psoriasis duration, tender/swollen joint count, and bone erosion were found among the groups.

Dkk-1 level was elevated in sera of patients with PsA

As shown in Figure 1, Dkk-1 was elevated in 68.1% (47/69) of the patients with PsA, 46.2% (18/39) of RA patients, and 9.5% (2/21) of HCs. Serum Dkk-1 level in PsA patients (9.269±3.276 ng/mL) was significantly higher than that in patients with RA (7.862±2.487 ng/mL, t = 2.506, P = 0.027) and HCs (6.250±1.102 ng/mL, t = 4.323, P < 0.010). In addition, Dkk-1 was increased in RA patients compared with HCs (t = 2.125, P = 0.036).

Correlation between Dkk-1 and clinical features of PsA

The correlations between Dkk-1 and clinical features of PsA are presented in Table 2. An increased level of Dkk-1 was correlated with elevated swollen joint count (r = 0.370, P < 0.010), number of platelets (r = −0.341, P < 0.010), C3 (r = −0.530, P < 0.001), and C4 (r = −0.354, P < 0.010) [Table 2 and Figure 2].
Table 1: Characteristics of PsA patients, RA patients, and healthy controls.

| Variables                  | PsA (n = 69) | RA (n = 39) | HCs (n = 21) | PsA vs RA | PsA vs HCs | RA vs HCs |
|----------------------------|--------------|-------------|--------------|-----------|------------|-----------|
| Age (years)                | 52.7 ± 13.0  | 55.5 ± 12.8 | 50.4 ± 9.3   | 1.270 *   | 0.285      |           |
| Female/male (n)            | 39/50        | 25/14       | 12/9         | 0.624     | 0.732      |           |
| Duration of arthritis (years) | 5.0 (1.6, 13.0) | 9.0 (3.0, 20.0) | NA          | -1.684 *  | 0.092      |           |
| Duration of psoriasis (years) | 12.0 (5.0, 20.0) | NA         | NA          | -         | -          |           |
| Family history of Ps or PsA, n (%) | 12 (17.4) | NA         | NA          | -         | -          |           |
| Uveitis, n (%)            | 32 (46.4)    | 46 (58.2)   | 26 (37.7)    | -         | -          | -         |
| Enthesitis, n (%)         | 19 (27.5)    | 30 (38.5)   | 22 (30.3)    | 0.070     | 0.035      |           |
| Dactylitis, n (%)         | 7 (10.1)     | 10 (12.8)   | 8 (11.3)     | -         | -          |           |
| Nail psoriasis, n (%)     | 30 (43.5)    | 33 (41.0)   | 24 (34.8)    | -         | -          |           |
| Swollen joint count, 0–44, n (%) | 3.0 (0, 8.0) | 4.0 (2.0, 7.0) | NA          | -1.445 *  | 0.148      |           |
| Tender joint count, 0–46, n (%) | 6.0 (2.0, 12.5) | 8.0 (5.0, 12.0) | NA          | -1.400 *  | 0.161      |           |
| HLA-B27-positive, n (%)   | 14 (20.3)    | 20 (25.6)   | 10 (14.3)    | -         | -          |           |
| Anti-CCP-positive, n (%)  | 4 (5.8)      | 5 (6.4)     | 4 (5.8)      | -         | -          |           |
| Sacroiliitis, n (%)       | 32 (46.4)    | 46 (58.2)   | 26 (37.7)    | -         | -          |           |
| Bone erosion, n (%)       | 26 (37.7)    | 39 (49.4)   | 25 (36.5)    | -         | -          |           |

Age and disease duration are respectively presented as mean ± SD and median (P25, P75). *Differences were analyzed by one-way analysis of variance (ANOVA) with Holm-Sidak multiple comparisons test for three groups, the statistics value was F. †Differences were analyzed by non-parametric test and the value was Z. Anti-CCP: Anti-cyclic citrullinated peptide; HCs: Healthy controls; HLA-B27: Human leukocyte antigen-B27; NA: Not assessed; Ps: Psoriasis; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; RF: Rheumatoid factor; SD: Standard deviation.

Figure 1: Serum Dkk-1 levels in patients with PsA and controls RA and HC. †P < 0.05, ‡P < 0.01. Dkk-1: Dickkopf-1; HC: Healthy controls; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis.

Dkk-1 and bone erosion in PsA

Using ROC curve analyses, a Dkk-1 cut-off value of 7.651 ng/mL was determined to distinguish the group with elevated Dkk-1 level (n = 47) from the group with normal Dkk-1 level (n = 22). The features of these two groups are shown in Table 3. The swollen joint count was higher in PsA patients with elevated Dkk-1 compared with those with normal Dkk-1 (4.0 vs. 1.0, Z = -2.103, P = 0.035). C3 was significantly lower in the elevated Dkk-1 group than the normal Dkk-1 group (1.11 ± 0.34 vs. 1.29 ± 0.26, t = -2.133, P = 0.037). In terms of radiographic features, sacroiliitis was observed in 57.4% (27/47) of patients with elevated Dkk-1, which was significantly higher than those with normal Dkk-1 levels (22.7%, χ² = 7.264, P < 0.010); the frequencies of RAD and bone erosion were significantly higher in PsA patients with elevated Dkk-1 than those with normal Dkk-1 (63.8% vs. 36.4%, χ² = 4.569, P = 0.033; 46.8% vs. 18.2%, χ² = 5.230, P = 0.022). Moreover, the Sharp score was notably higher in PsA patients with elevated Dkk-1 levels than those with normal Dkk-1 levels (9.0 [0, 17.0] vs. 3.0 [0, 7.0], Z = -2.067, P = 0.039). No significant differences in sex ratio, age, arthritis/psoriasis

Table 2: Correlation analysis of serum Dkk-1 and clinical features.

| Variables                  | Pearson or Spearman rank correlation coefficient (r) | P values |
|----------------------------|-----------------------------------------------------|----------|
| Age                        | -0.048                                              | 0.693    |
| Duration of arthritis      | -0.086                                              | 0.483    |
| Duration of psoriasis      | 0.005                                               | 0.971    |
| Tender joint count, 0–46 joints | 0.097                                           | 0.429    |
| Swollen joint count, 0–44 joints | 0.370                                           | <0.010   |
| JSN score                  | 0.156                                               | 0.199    |
| Erosion score              | 0.235                                               | 0.035    |
| Sharp score                | 0.201                                               | 0.098    |
| WBC                        | -0.186                                              | 0.126    |
| Hb                         | -0.019                                              | 0.875    |
| PLT                        | -0.341                                              | <0.010   |
| ESR                        | 0.090                                               | 0.461    |
| CRP                        | -0.118                                              | 0.335    |
| IgA                        | -0.035                                              | 0.778    |
| IgG                        | -0.086                                              | 0.486    |
| IgM                        | -0.046                                              | 0.708    |
| Complement C3              | -0.530                                              | <0.010   |
| Complement C4              | -0.334                                              | <0.010   |

CRP: C-reactive protein; Dkk-1: Dickkopf-1; ESR: Erythrocyte sedimentation; Hb: Hemoglobin; Ig: Immunoglobulin; JSN: Joint space narrowing; PLT: Platelet; WBC: White blood cell.
duration, tender joint count, the frequency of nail psoriasis, dactylitis, enthesitis, uveitis, autoantibodies including RF, anti-CCP, and HLA-B27 were found between the two groups.

**Risk factors for bone erosion in PsA patients**

We identified independent risk factors associated with bone erosion in PsA patients using binary logistic regression analysis [Table 4]. Elevated Dkk-1 level was considered an independent risk factor of bone erosion in the multivariate model (odds ratio 4.440, 95% confidence interval: 1.246–15.817, \( P = 0.021 \)).

**Discussion**

In this study, we demonstrated that serum Dkk-1 was significantly elevated in PsA patients compared with RA patients and HCs, supporting the idea that Dkk-1 might be involved in the pathogenesis of PsA. A key finding of our study is that increased Dkk-1 was correlated with bone erosion in PsA patients.
PsA is a chronic autoimmune disorder that attacks enthesi and synovial joints, resulting in bone destruction. Progressive bone erosion and new bone formation are hallmarks of PsA, so finding the main molecules involved in bone erosion is essential for determining the mechanism of PsA. Dkk-1 is a key inhibitor in Wnt signaling by binding to the Wnt co-receptor low density lipoprotein receptor-related protein 5/6 (LRP5/6).\textsuperscript{[18,19]} Wnt signaling via LRP5 impacts accrual and is crucial for peak bone mass establishment.\textsuperscript{[20]} The LPR5 mutation causes high bone density, by reducing the action of a normal antagonist of the Wnt-mediated pathway and thus promoting Wnt signaling.\textsuperscript{[21]} These findings indicate that Dkk-1 is a potential treatment or prevention target of osteoporosis or bone erosion.\textsuperscript{[8,20-22]}

Dkk-1 functions directly in the differential remodeling of a joint architecture by diverse mechanisms. For example, an elevated level of Dkk-1 impairs bone formation by upregulating the expression of inflammatory cytokines including tumor necrosis factor (TNF).\textsuperscript{[23,24]} Additionally, lower Dkk-1 contributes to the appearance of osteophytes.\textsuperscript{[24]} PsA is a heterogenous disease that may manifest both patterns of osteopathology, either bone loss or bone remodeling.\textsuperscript{[13,4,16]} The mechanism of PsA joint remodeling is unknown thus far.

Fassio \textit{et al}.\textsuperscript{[25]} indicated that Dkk-1 was lower in PsA patients compared with the RA and HC groups, while a study from New Zealand reported that PsA patients had increased Dkk-1 concentrations of sera compared with HCs.\textsuperscript{[9]} Jadon \textit{et al}.\textsuperscript{[26]} demonstrated that Dkk-1 was significantly higher in PsA patients with axial arthritis than without it. The elevated concentration of circulating Dkk-1 in this study differs from the results from Fassio \textit{et al}. A further consideration is that sera Dkk-1 levels may be varied in different phenotypes. In our study, 55.1% of PsA patients had axial arthritis. The results implied that high levels of Dkk-1 indicated the involvement of axial arthritis in PsA.

Our results showed that patients with elevated Dkk-1 levels had higher swollen joint counts than patients with normal Dkk-1, suggesting that elevated Dkk-1 may indicate more severe disease activity. Elevated Dkk-1 levels in PsA patients have been shown with a radiographic damage score, including Sharp/van der Heijde score and the sacroiliitis ratio. Moreover, patients with elevated Dkk-1 have an increased risk of bone erosion. Increased sera Dkk-1 concentrations have been reported in PsA patients with axial arthritis\textsuperscript{[26]}; similar results are observed in studies of ankylosing spondylitis.\textsuperscript{[27,28]} Because more than half of the PsA patients suffered from inflammatory RAD in our study, we hypothesized that Dkk-1 may be used as a serum marker of radiographic damage in axial spondyloarthritis of PsA patients, which was consistent with conclusions about ankylosing spondylitis from a meta-analysis by Wu \textit{et al}.\textsuperscript{[29]}

Dkk-1 is a key inhibitory factor of osteoblastic activity, and its circulation concentration is confirmed to be associated with the process of bone erosion in RA.\textsuperscript{[30]} Dkk-1 has also been observed to be associated with spondyloarthritis and even with erosive arthritis in patients with systemic lupus erythematosus.\textsuperscript{[31]} The mechanism of Dkk-1 in bone destruction seems to be regulated by cytokines in the local inflammatory microenvironments of joints, such as TNF-\alpha, interleukin (IL)-6, IL-8, IL-17, and matrix metalloproteinases.\textsuperscript{[12,25,32,33]} The cytokines interacted within a complicated regulatory network in inflammatory arthritis, modulating the interactions among immune cells, fibroblast-like synoviocytes, and osteoblasts. Bone erosion and bone formation are successive processes in PsA, indicating that elevation of serum Dkk-1 is a predictive indicator for bone erosion. Further research of the function of Dkk-1 may help to identify the mechanism of bone erosion in inflammatory arthritis.

There are several limitations to our study. First, statistical bias could not be avoided because the sample size was quite limited, and stratification according to the disease duration and severity was not performed, and the sample size was calculated using a univariate method that does not control the confounding effect, and there were fewer HCs than the pre-defined sample size. Second, selection bias could not be ruled out because all cases were collected from a single center in this study. Third, complete longitudinal data such as psoriasis area and severity index score were lacking due to the retrospective design. Therefore, larger sample-based multicenter studies are needed for more accurate information in the future.

To conclude, this study has shown that serum Dkk-1 level is abnormally elevated in PsA patients. Increased Dkk-1 levels are associated with sacroiliitis and might be involved in bone erosion in PsA patients. Further studies of the role of Dkk-1 might be useful in understanding the mechanism of PsA.

\textbf{Funding}  
This work was supported by grants from the National Natural Science Foundation of China (Nos. 81771678, 81801617).

\textbf{Conflicts of interest}  
None.
References

1. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs 2002;62:2447–2457. doi: 10.2165/00003495-200262170-00004.

2. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Bohnecke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–1394. doi: 10.1136/ard.2008.094946.

3. Sanna S, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis 2006;65:478–481. doi: 10.1136/ard.2005.039826.

4. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthropathies (PSA) - an analysis of 220 patients. Q J Med 1987;62:127–141.

5. Krause U, Gregory CA. Potential of modulating Wnt signaling pathway toward the development of bone anabolic agent. Curr Mol Pharmacol 2012;5:164–173. doi: 10.2174/1874467211205020164.

6. Mao B, Wu L, Li Y, Hoppe D, Stanké P, Glinka A, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321–325. doi: 10.1038/35077108.

7. Pijpe J. Attenuation of Wnt/β-catenin signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007;6:71. doi: 10.1186/1476-4598-6-71.

8. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X. Dickkopf-1 is a biomarker for bone erosion in patients with psoriatic arthritis. Chin Med J (Engl) 2020;133:2583–2588. doi: 10.1097/CMA.0000000000001612.

9. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, et al. Serum bone turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. Arthritis Res Ther 2017;19:210. doi: 10.1186/s13075-017-1417-7.

10. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from synovemophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:572–574. doi: 10.1136/annrheumdis-2011-202016.

11. Jadon DR, Sengupta R, Nightingale A, Lu H, Dunphy J, Green A, et al. Serum autoantibodies in psoriatic arthritis: are they of pathogenic relevance? Chin Med J 2020;133:1394. doi: 10.1136/ard.2005.039826.

12. Fassio A, Idolazzi L, Polzer B, Marzocchi R, Osvaldina J, Omonsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156–163. doi: 10.1038/nm1538.

13. Fassio A, Gatti D, Rossini M, Idolazzi L, Gioiello A, Adami G, et al. Seckinkuminab produces a quick knockdown of pathological dickkopf-1 in patients with psoriatic arthritis. Clin Exp Rheumatol 2019;37:133–136.

14. Jadon DR, Nightingale AL, McHugh NJ, Lindsay MA, Korendowych JF, Buoncristiani A, Anderson AE, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62:150–158. doi: 10.1002/art.27231.

15. Wu M, Chen M, Ma Y, Yang J, Han R, Yuan Y, et al. Dickkopf-1 in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta 2018;481:177–183. doi: 10.1016/j.cca.2018.03.010.

16. Seror R, Bouadous S, Pavy S, Nocturne G, Schaeverbeke T, Saraux A, et al. Increased Dickkopf-1 in recent-onset rheumatoid arthritis is a new biomarker of structural severity. Data from the ESPOR Cohort. Sci Rep 2016;6:18421. doi: 10.1038/srep18421.

17. Long L, Liu Y, Wang S, Zhao Y, Guo J, Yu P, et al. Dickkopf-1 as a potential biomarker to evaluate bone erosion in systemic lupus erythematosus. J Clin Immunol 2010;30:669–675. doi: 10.1007/s10875-010-9436-2.

18. Zhu J, Shi XF, Chu CQ. Autoantibodies in psoriatic arthritis: are they of pathogenic relevance? Chin Med J 2020;133:2899–2901. doi: 10.1097/cm9.0000000000001228.

19. Farrugia M, Baron B. The role of TNF-α antagonists in patients with psoriatic arthritis. Drugs 2002;62:2463–2470. doi: 10.1006/dctx.2001.0597.

20. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, et al. Isolation and biochemical characterization of the human Dkk-1 pathway toward the development of bone anabolic agent. Curr Mol Med 2002;6:2750. doi: 10.1016/j.ccm.2006.09.003.

21. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Bohnecke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–1394. doi: 10.1136/ard.2008.094946.

22. Fassio A, Idolazzi L, Polzer B, Marzocchi R, Osvaldina J, Omonsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156–163. doi: 10.1038/nm1538.

23. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from synovemophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:572–574. doi: 10.1136/annrheumdis-2011-202016.

24. Jadon DR, Sengupta R, Nightingale A, Lu H, Dunphy J, Green A, et al. Serum autoantibodies in psoriatic arthritis: are they of pathogenic relevance? Chin Med J 2020;133:1394. doi: 10.1136/ard.2005.039826.

25. Fassio A, Gatti D, Rossini M, Idolazzi L, Gioiello A, Adami G, et al. Seckinkuminab produces a quick knockdown of pathological dickkopf-1 in patients with psoriatic arthritis. Clin Exp Rheumatol 2019;37:133–136.

26. Jadon DR, Sengupta R, Nightingale A, Lu H, Dunphy J, Green A, et al. Serum autoantibodies in psoriatic arthritis: are they of pathogenic relevance? Chin Med J 2020;133:1394. doi: 10.1136/ard.2005.039826.

27. Wu M, Chen M, Ma Y, Yang J, Han R, Yuan Y, et al. Dickkopf-1 in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta 2018;481:177–183. doi: 10.1016/j.cca.2018.03.010.

28. Seror R, Bouadous S, Pavy S, Nocturne G, Schaeverbeke T, Saraux A, et al. Increased Dickkopf-1 in recent-onset rheumatoid arthritis is a new biomarker of structural severity. Data from the ESPOR Cohort. Sci Rep 2016;6:18421. doi: 10.1038/srep18421.

29. Long L, Liu Y, Wang S, Zhao Y, Guo J, Yu P, et al. Dickkopf-1 as a potential biomarker to evaluate bone erosion in systemic lupus erythematosus. J Clin Immunol 2010;30:669–675. doi: 10.1007/s10875-010-9436-2.

30. Zhu J, Shi XF, Chu CQ. Autoantibodies in psoriatic arthritis: are they of pathogenic relevance? Chin Med J 2020;133:2899–2901. doi: 10.1097/cm9.0000000000001228.

31. Farrugia M, Baron B. The role of TNF-α antagonists in patients with psoriatic arthritis. Drugs 2002;62:2463–2470. doi: 10.1006/dctx.2001.0597.